{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:06:47Z","timestamp":1787922407586,"version":"build-2784847793"},"reference-count":94,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Mental Health Nurs"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The global rise in methamphetamine use and its negative effects warrants the need for research exploring harm reduction and treatment interventions for individuals with methamphetamine use disorder. Agonist medications have been utilized for years for the treatment of heroin and opioid addiction, but have yet to be incorporated into mainstream Canadian practice for methamphetamine dependence. This review aims to provide an overview of the current trends of prescription psychostimulant usage for individuals with methamphetamine use disorder from a Canadian perspective, identifies the barriers to accessing prescription psychostimulants for methamphetamine use disorder and highlights the nursing clinical practice implications in caring for individuals with the disorder. Discourse on the sustained abstinence and harm reduction debate is presented from the perspective of methamphetamine abuse is provided along with the neuropsychiatric complications of chronic methamphetamine use. The impacts of specific prescription psychostimulants on cognition are discussed as is the use of neuroimaging techniques to assess neuronal damage in methamphetamine users. Sign of toxicity, overdose and the contraindications for use of these prescription psychostimulants is also presented. The implications to nursing clinical practice in caring for this population is provided, touching on the clinical presentation of methamphetamine use, completing thorough assessment and screening and patient education. The findings of this review indicate the need for further research in this area exploring the benefits of prescription psychostimulants as a harm reduction and treatment intervention for the global problem of methamphetamine dependence.<\/jats:p>","DOI":"10.1111\/inm.13144","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T04:09:08Z","timestamp":1680062948000},"page":"1225-1242","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prescription psychostimulants as a harm reduction and treatment intervention for methamphetamine use disorder and the implications for nursing clinical practice: A scoping review of the literature"],"prefix":"10.1111","volume":"32","author":[{"given":"Don","family":"Leidl","sequence":"first","affiliation":[{"name":"College of Nursing University of Saskatchewan  Saskatoon Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"Takhar","sequence":"additional","affiliation":[{"name":"College of Nursing University of Saskatchewan  Saskatoon Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Li","sequence":"additional","affiliation":[{"name":"College of Nursing University of Saskatchewan  Saskatoon Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954\u2010015\u20100088\u20104"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.07.007"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/1364557032000119616"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0004867417748750"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108060"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2015.07.028"},{"key":"e_1_2_12_8_1","unstructured":"Bierness D.(2008)Harm Reduction:What's in a name? Canadian Center on Substance Abuse National Policy Working Group. Available from:http:\/\/www.ccsa.ca\/Resource%20Library\/ccsa0115302008e.pdf[Accessed 30th January 2023]."},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.21037\/tp.2017.08.02"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521\u20100391.2009.00024.x"},{"key":"e_1_2_12_11_1","unstructured":"Canadian Institute for Health Information. (2019)Common challenges shared priorities measuring access to home and community care to mental health and addictions services in Canada. Available from:https:\/\/www.cihi.ca\/sites\/default\/files\/document\/shp\u2010companion\u2010report\u2010en.pdf[Accessed 30th January 2023]."},{"key":"e_1_2_12_12_1","unstructured":"CCENDU \u2013 Canadian Centre on Substance Use and Addiction. (2022)CCENDU Bulletin: An update on stimulant use and related harms in Canada and the United States. Available from:https:\/\/www.ccsa.ca\/sites\/default\/files\/202212\/CCENDU%202022%20Stimulants%20Update.pdf[Accessed 30th January 2023]."},{"key":"e_1_2_12_13_1","unstructured":"CCSA \u2013 Canadian Centre on Substance Use and Addiction. (2020a)Methamphetamine. [Canadian Drug Summary]. Available from:https:\/\/www.ccsa.ca\/sites\/default\/files\/2020\u201003\/CCSA\u2010Canadian\u2010Drug\u2010Summary\u2010Methamphetamine\u20102020\u2010en.pdf[Accessed 30th January 2023]."},{"key":"e_1_2_12_14_1","unstructured":"CCSA \u2013 Canadian Centre on Substance Use and Addiction. (2020b)Methamphetamine the Respiratory System and COVID\u201019. [Report]. Available from:https:\/\/www.ccsa.ca\/sites\/default\/files\/2020\u201005\/CCSA\u2010COVID\u201019\u2010Methamphetamine\u2010Respiratory\u2010System\u2010Report\u20102020\u2010en_0.pdf[Accessed 30th January 2023]."},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606\u2010019\u201005074\u20108"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0000000000000168"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.08.003"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300600"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010013\u20100025\u2010y"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2012.179"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2009.11.007"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360\u20100443.2007.01773.x"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2018.0049"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.54.6.1344"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102020\u2010044696"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2018.02.001"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.tcam.2013.03.002"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107891"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.2012.04474.x"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/07347324.2017.1355223"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.307"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.13115"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100043\u2010105500"},{"key":"e_1_2_12_34_1","unstructured":"Hedegaard H. Minino A.&Warner M.(2020)Drug overdose deaths in the United States 1999\u20132019. NCHS Data Brief no 394. Available from:https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db394\u2010H.pdf[Accessed 30th January 2023]."},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.11.023"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1348\/000712609X435742"},{"key":"e_1_2_12_37_1","volume-title":"Impact of methamphetamine abuse in Canada: report of the standing committee on health","author":"HESA \u2013 House of Commons","year":"2019"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14878"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15m09872"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.14688"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2015.1027903"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008480\u2010200204000\u201000013"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2015.10.009"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/DBP.0b013e31824afea1"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465\u20103362.2012.00473.x"},{"key":"e_1_2_12_46_1","first-page":"174","volume-title":"Addictions: a comprehensive guidebook","author":"Ling W.","year":"2013"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12608"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145713001594"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.04.039"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360\u20100443.2009.02717.x"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.14745\/ccdr.v47i12a01"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550490601082783"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2001.10400463"},{"issue":"1","key":"e_1_2_12_54_1","first-page":"9","article-title":"When ADHD and substance abuse disorders coexist","volume":"19","author":"Martinez\u2010Raga J.","year":"2019","journal-title":"Attention Magazine"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1006\/nimg.2000.0610"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7006a4"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.18\u201020\u201008417.1998"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1080\/00952990802342907"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0b013e3181b591e0"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.01.018"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12518"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108180"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12109"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00137"},{"key":"e_1_2_12_65_1","unstructured":"National Institute of Drug Abuse. (2021)What is methamphetamine?[Research Report]. Available from:https:\/\/www.drugabuse.gov\/publications\/research\u2010reports\/methamphetamine\/what\u2010methamphetamine[Accessed 30th January 2023]."},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.15.3.317"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1246"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13011\u2010021\u201000399\u20102"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.11.016"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chc.2016.02.004"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.0246"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009695.pub2"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2018.01.021"},{"key":"e_1_2_12_74_1","volume-title":"Opioid\u2010 and stimulant\u2010related harms in Canada","author":"Public Health Agency of Canada \u2013 Special Advisory Committee on the Epidemic of Opioid Overdoses","year":"2022"},{"issue":"3","key":"e_1_2_12_75_1","first-page":"146","article-title":"Current research on methamphetamine: epidemiology, medical and psychiatric effects, treatment, and harm reduction efforts","volume":"6","author":"Radfar S.","year":"2014","journal-title":"Addiction and Health"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40199\u2010015\u20100092\u2010y"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005721\u2010200401000\u201000007"},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1037\/0000133-024"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11065\u2010007\u20109031\u20100"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.8.1206"},{"key":"e_1_2_12_81_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360\u20100443.2001.96912898.x"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1080\/01612840.2018.1553003"},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263\u2010020\u201000711\u2010x"},{"key":"e_1_2_12_84_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650802175595"},{"key":"e_1_2_12_85_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h5203"},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.14745\/ccdr.v46i05a07"},{"key":"e_1_2_12_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213\u2010020\u201005563\u20103"},{"key":"e_1_2_12_88_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0713\u201004.2004"},{"key":"e_1_2_12_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.10.005"},{"key":"e_1_2_12_90_1","unstructured":"United Nations Office on Drugs and Crime. (2021)Global overview: Drug demand and drug supply. [World Drug Report]. Available from:https:\/\/www.unodc.org\/res\/wdr2021\/field\/WDR21_Booklet_2.pdf[Accessed 30th January 2023]."},{"key":"e_1_2_12_91_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.3.377"},{"key":"e_1_2_12_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2008.05.022"},{"key":"e_1_2_12_93_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.11.1909"},{"key":"e_1_2_12_94_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.21\u201002\u2010j0001.2001"},{"key":"e_1_2_12_95_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.2.242"}],"container-title":["International Journal of Mental Health Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/inm.13144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T09:49:51Z","timestamp":1693820991000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/inm.13144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":94,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1111\/inm.13144"],"URL":"https:\/\/doi.org\/10.1111\/inm.13144","archive":["Portico"],"relation":{},"ISSN":["1445-8330","1447-0349"],"issn-type":[{"value":"1445-8330","type":"print"},{"value":"1447-0349","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]},"assertion":[{"value":"2022-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}